BridgeBio Pharma, Inc. (BBIO): Price and Financial Metrics
BBIO Price/Volume Stats
| Current price | $25.03 | 52-week high | $44.32 |
| Prev. close | $25.46 | 52-week low | $12.75 |
| Day low | $24.44 | Volume | 1,540,268 |
| Day high | $25.78 | Avg. volume | 1,762,584 |
| 50-day MA | $29.96 | Dividend yield | N/A |
| 200-day MA | $30.76 | Market Cap | 4.40B |
BBIO Stock Price Chart Interactive Chart >
BridgeBio Pharma, Inc. (BBIO) Company Bio
BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 development programs includes product candidates from early discovery to late-stage development. The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and in preclinical development for the treatment of achondroplasia; and BBP-631, a preclinical adeno-associated virus, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia caused by 21OHD. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.
Latest BBIO News From Around the Web
Below are the latest news stories about BRIDGEBIO PHARMA INC that investors may wish to consider to help them evaluate BBIO as an investment opportunity.
With BridgeBio Pharma's DNA, the Stock Could Continue to Soar HigherBridgeBio Pharma has made a base pattern. The company finds, develops, and delivers breakthrough medicines for genetic diseases - a worthy mission. In this daily bar chart of BBIO, below, I can see that prices have climbed four-fold in the past twelve months. |
13 High Growth Healthcare Stocks to BuyIn this article, we will take a look at 13 high growth healthcare stocks to buy. To skip our analysis of the recent market activity, you can go directly to see the 5 Best High Growth Healthcare Stocks to Buy. For the purpose of this article, we have defined high growth stocks as stocks that […] |
3 Russell 2000 Stocks That Are About to Get Absolutely CrushedThe Russell 2000 has only begun closing its wide gap with other indices, but investors should be weary of these three stocks to sell. |
BridgeBio Announces First Child Dosed in PROPEL 3, its Phase 3 Clinical Trial for Infigratinib in Children with Achondroplasia- BridgeBio has dosed the first child in PROPEL 3, a one-year, 2:1 randomized, placebo-controlled Phase 3 pivotal trial evaluating the efficacy and safety of infigratinib in children with achondroplasia - The U.S. Food and Drug Administration (FDA) and European Union (EU) European Medicines Agency (EMA) shared positive feedback that the PROPEL 3 trial design would be acceptable as a registrational study to support a marketing application - Data from PROPEL 2, BridgeBio’s Phase 2 clinical trial o |
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)PALO ALTO, Calif., Dec. 08, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on December 05, 2023, the compensation committee of BridgeBio’s board of directors granted thirty new employees restricted stock units for an aggregate of 147,373 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock |
BBIO Price Returns
| 1-mo | -14.83% |
| 3-mo | -30.61% |
| 6-mo | 2.41% |
| 1-year | 70.74% |
| 3-year | 37.86% |
| 5-year | N/A |
| YTD | -38.00% |
| 2023 | 429.79% |
| 2022 | -54.32% |
| 2021 | -29.63% |
| 2020 | 102.88% |
| 2019 | N/A |
Loading social stream, please wait...